SCHEMBL503966

SCHEMBL503966

O=C(O)CCCCC(=O)CC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
TSHR P16473 4/20 0.61
NFKB1 P19838 2/20 0.61
PMP22 Q01453 1/20 0.61
FOLH1 Q04609 1/20 0.57
SLC22A6 Q4U2R8 2/20 0.56
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
GPR84 Q9NQS5 4/20 0.50
FFAR1 O14842 2/20 0.50
FFAR4 Q5NUL3 2/20 0.50
AKR1B1 P15121 1/20 0.50
CYP2D6 P10635 1/20 0.50
PRMT1 Q99873 1/20 0.48
PPARG P37231 4/20 0.48
PPARD Q03181 4/20 0.48
PPARA Q07869 4/20 0.48
HDAC11 Q96DB2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TDP1 Q9NUW8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503466 0.97 TSHR (0.67) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL503360 0.97 TSHR (0.67) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL11622180 0.97 TSHR (0.67) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL10861269 0.97 TSHR (0.67) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL284957 0.94 SLC22A6 (0.65) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL9185822 0.94 LMNA (0.53) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL12568555 0.91 LMNA (0.69) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL11438692 0.91 TSHR (0.56) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL8751902 0.91 TSHR (0.56) LMNATSHRNFKB1PMP22FOLH1
SCHEMBL6265240 0.91 TSHR (0.56) LMNATSHRNFKB1PMP22FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10273476-A None JP disclosed
US-20240141397-A1 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS AGAIN BIO APS (DK) 2024-05-02 US disclosed
US-20190300918-A1 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS AGAIN BIO APS (DK) 2019-10-03 US disclosed
EP-3314002-A1 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS Genomatica, Inc. (US) 2018-05-02 EP disclosed
WO-2016209883-A1 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS GENOMATICA, INC. (US) 2016-12-29 WO disclosed
US-8435718-B2 Upper layer-forming composition and photoresist patterning method JSR CORPORATION (JP) 2013-05-07 US disclosed
EP-1950610-B1 IMMERSION LITHOGRAPHIC COMPOSITION FOR FORMING UPPER FILM AND METHOD FOR FORMING PHOTORESIST PATTERN JSR CORP (JP) 2012-05-02 EP disclosed
US-20120028198-A1 UPPER LAYER-FORMING COMPOSITION AND PHOTORESIST PATTERNING METHOD JSR CORPORATION (JP) 2012-02-02 US disclosed
US-20100003615-A1 UPPER LAYER-FORMING COMPOSITION AND PHOTORESIST PATTERNING METHOD JSR CORPORATION (JP) 2010-01-07 US disclosed
EP-1950610-A1 COMPOSITION FOR FORMING UPPER FILM AND METHOD FOR FORMING PHOTORESIST PATTERN JSR Corporation (JP) 2008-07-30 EP disclosed
EP-1758913-A1 RUTHENIUM COMPLEXES OF PHOSPHINE-AMINOPHOSPHINE LIGANDS EASTMAN CHEMICAL COMPANY (US) 2007-03-07 EP disclosed
WO-2006012027-A1 RUTHENIUM COMPLEXES OF PHOSPHINE-AMINOPHOSPHINE LIGANDS EASTMAN CHEMICAL COMPANY (US) 2006-02-02 WO disclosed
US-6939981-B1 ruthenium complexes of phosphine-aminophosphine ligands are useful as catalyst for the asymmetric hydrogenation of beta -ketoesters to beta -hydroxyesters EASTMAN CHEMICAL COMPANY (US) 2005-09-06 US disclosed
EP-1176135-B1 Process for producing optically active alcohol TAKASAGO PERFUMERY CO LTD (JP) 2005-06-15 EP disclosed
US-6492545-B2 Process for producing optically active alcohol TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-12-10 US disclosed
US-20020035283-A1 Process for producing optically active alcohol TAKASAGO INTERNATIONAL CORPORATION 2002-03-21 US disclosed
EP-1176135-A1 Process for producing optically active alcohol Takasago International Corporation (JP) 2002-01-30 EP disclosed
US-6229042-B1 INTERMEDIATES FOR THE SYNTHESIS OF ENANTIOMERICALLY PURE ALPHA-LIPOIC ACID; SAID HYDROGENATION INCLUDES PRESENCE OF RUTHENIUM-PHOSPHINE COMPLEX ASTA MEDICA AKTIENGESELLSCHAFT (DE) 2001-05-08 US disclosed
US-6013833-A USING A CATALYST OF A COMPLEX OF RUTHENIUM AND AN OPTICALLY ACTIVE PHOSPHINE; PRODUCING (R)-3-HYDROXYOCTANEDIOIC ACID DIESTERS AS CHEMICAL INTERMEDIATES OF ALPHA-LIPOIC ACID ASTA MEDICA AKTIENGESELLSCHAFT (DE) 2000-01-11 US disclosed
JP-H10273476-A PRODUCTION OF ENANTIOMER PURE DIESTER OF 3-HYROXYOCTANEDIOIC ACID, DIESTER OF (R)-3-HYDROXYOCTANEDIOIC ACID AND PRODUCTION OF (R)-(+)-AND (S)-(-)-ALFA-LIPOIC ACID ASTA MEDICA AG 1998-10-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035283-A1 Process for producing optically active alcohol ADH1A, ADH5, ADH1C LMNA 4480/4885TSHR 2757/4885NFKB1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.